Mineralys Secures Full Lorundrostat IP Rights & $500M Non-Dilutive Financing
MLYS has more than doubled off its 52-week low of $12.59.
Summary
Mineralys Therapeutics secured full, royalty-free intellectual property rights for its lead drug lorundrostat and obtained a $500 million non-dilutive term loan facility, significantly strengthening its financial and strategic position ahead of potential commercialization.
Key Events · Financing and Capital Events · MLYS
-
Secured Full Lorundrostat IP Rights
Mineralys entered an amendment with Tanabe Pharma, paying $200 million upfront and committing to up to $365 million in future milestones, to gain an exclusive, worldwide, royalty-free, perpetual license for lorundrostat and eliminate all future royalty payments. This consolidates control over its lead asset.
-
Obtained $500 Million Non-Dilutive Loan Facility
The company secured a five-year senior secured term loan facility of up to $500 million from BioPharma Credit PLC. An initial $100 million was drawn, with additional tranches contingent on FDA approval of lorundrostat and achievement of certain net sales milestones.
Analysis · MLYS · Life Sciences
Mineralys Therapeutics has made two highly significant moves to strengthen its position ahead of the potential commercial launch of lorundrostat. First, by paying $200 million upfront and committing to additional milestones, the company gains full, royalty-free, and perpetual control over its lead drug's intellectual property. This eliminates a major ongoing cost and maximizes future profitability. Second, securing a $500 million non-dilutive term loan facility, with an immediate $100 million draw, provides substantial capital runway. The milestone-based tranches align funding with key regulatory and commercial successes, significantly de-risking the company's financial outlook as it approaches a critical FDA decision for lorundrostat.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MLYS was trading at $29.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $12.59 to $47.65. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.